AP2174A - Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflamation. - Google Patents

Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflamation.

Info

Publication number: AP2174A
Authority: AP; ARIPO
Prior art keywords: inflamation; hiv; treatment; receptor antagonist; antagonist activity
Prior art date: 2003-10-03

Application number

AP2006003580A

Other languages

English (en)

Other versions

AP2006003580A0 (en

Inventor

Paul Anthony Stupple

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-03

Filing date

2004-09-28

Publication date

2010-11-20

2003-10-03 Priority claimed from GBGB0323236.0A external-priority patent/GB0323236D0/en

2003-10-27 Priority claimed from GB0325020A external-priority patent/GB0325020D0/en

2004-08-19 Priority claimed from GB0418566A external-priority patent/GB0418566D0/en

2004-09-28 Application filed by Pfizer filed Critical Pfizer

2006-04-30 Publication of AP2006003580A0 publication Critical patent/AP2006003580A0/xx

2010-11-20 Application granted granted Critical

2010-11-20 Publication of AP2174A publication Critical patent/AP2174A/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

AP2006003580A 2003-10-03 2004-09-28 Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflamation. AP2174A (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GBGB0323236.0A GB0323236D0 (en)	2003-10-03	2003-10-03	Chemical compounds
GB0325020A GB0325020D0 (en)	2003-10-27	2003-10-27	Chemical compounds
GB0418566A GB0418566D0 (en)	2004-08-19	2004-08-19	Tropane derivatives
PCT/IB2004/003153 WO2005033107A1 (en)	2003-10-03	2004-09-28	Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation

Publications (2)

Publication Number	Publication Date
AP2006003580A0 AP2006003580A0 (en)	2006-04-30
AP2174A true AP2174A (en)	2010-11-20

Family

ID=34426592

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2006003580A AP2174A (en)	2003-10-03	2004-09-28	Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflamation.

Country Status (35)

Country	Link
US (2)	US7309790B2 (xx)
EP (1)	EP1682545B1 (xx)
JP (1)	JP4874107B2 (xx)
KR (1)	KR100777885B1 (xx)
AP (1)	AP2174A (xx)
AR (1)	AR045856A1 (xx)
AT (1)	ATE380813T1 (xx)
AU (1)	AU2004278158B2 (xx)
BR (1)	BRPI0414862A (xx)
CA (1)	CA2540834C (xx)
CY (1)	CY1107281T1 (xx)
DE (1)	DE602004010708T2 (xx)
DK (1)	DK1682545T3 (xx)
EA (1)	EA009941B1 (xx)
EC (1)	ECSP066475A (xx)
ES (1)	ES2295924T3 (xx)
GE (1)	GEP20084417B (xx)
HN (1)	HN2004000383A (xx)
HR (1)	HRP20080052T3 (xx)
IL (1)	IL174208A0 (xx)
MA (1)	MA28080A1 (xx)
MX (1)	MXPA06003749A (xx)
MY (1)	MY137609A (xx)
NO (1)	NO20061978L (xx)
NZ (1)	NZ545837A (xx)
OA (1)	OA13266A (xx)
PA (1)	PA8614301A1 (xx)
PE (1)	PE20050961A1 (xx)
PL (1)	PL1682545T3 (xx)
PT (1)	PT1682545E (xx)
RS (1)	RS20060198A (xx)
SI (1)	SI1682545T1 (xx)
TW (1)	TWI280244B (xx)
UY (1)	UY28546A1 (xx)
WO (1)	WO2005033107A1 (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20030762A1 (es)	2001-12-18	2003-09-05	Schering Corp	Compuestos heterociclicos como antagonistas nk1
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
CN1849318B (zh)	2003-07-30	2011-10-12	里格尔药品股份有限公司	用2,4-嘧啶二胺化合物预防和治疗自体免疫疾病的方法
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
KR101312225B1 (ko)	2005-06-08	2013-09-26	리겔 파마슈티칼스, 인크.	Ｊａｋ 경로의 억제를 위한 조성물 및 방법
JP2009528295A (ja)	2006-02-24	2009-08-06	ライジェルファーマシューティカルズ，インコーポレイテッド	Ｊａｋ経路の阻害のための組成物および方法
WO2007114921A2 (en)	2006-04-05	2007-10-11	Schering Corporation	Pharmaceutical formulations: salts of 8-[{1-(3,5-bis (trifluoromethy1)pheny1)-e thoxy}-methy1]-8-pheny1-1,7-diaza-spiro[4.5] decan-2-one and treatment methods using the same
WO2008030853A2 (en) *	2006-09-06	2008-03-13	Incyte Corporation	Combination therapy for human immunodeficiency virus infection
DE602007012363D1 (de)	2006-10-19	2011-03-17	Rigel Pharmaceuticals Inc	2,4-pyridimediamon-derivate als hemmer von jak-kinasen zur behandlung von autoimmunerkrankungen
WO2008085302A1 (en) *	2006-12-20	2008-07-17	Merck & Co., Inc.	Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
AR065802A1 (es) *	2007-03-22	2009-07-01	Schering Corp	Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
NZ585137A (en) *	2007-10-25	2012-07-27	Exelixis Inc	Tropane compounds useful as hsp90 inhibitors
PL2265607T3 (pl)	2008-02-15	2017-07-31	Rigel Pharmaceuticals, Inc.	Związki pirymidyno-2-aminowe i ich zastosowanie jako inhibitory kinaz JAK
US8138339B2 (en)	2008-04-16	2012-03-20	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases
NZ589315A (en)	2008-04-16	2012-11-30	Portola Pharm Inc	2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
CA2723185A1 (en)	2008-04-22	2009-10-29	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases
SG157299A1 (en)	2008-05-09	2009-12-29	Agency Science Tech & Res	Diagnosis and treatment of kawasaki disease
RU2017145628A (ru)	2009-08-14	2019-02-19	ОПКО Хельс, Инк.	Композиции антагонистов нейрокинина-1 для внутривенного введения
BR112012024522A2 (pt)	2010-04-02	2017-08-08	Phivco 1 Llc	combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio
US9102625B2 (en)	2010-11-01	2015-08-11	Portola Pharmaceuticals, Inc.	Nicotinamides as JAK kinase modulators
US20140271680A1 (en)	2011-08-12	2014-09-18	Universite Paris-Est Creteil Val De Marne	Methods and pharmaceutical compositions for treatment of pulmonary hypertension
EP2782579B1 (en)	2011-11-23	2019-01-02	Portola Pharmaceuticals, Inc.	Pyrazine kinase inhibitors
US9676756B2 (en)	2012-10-08	2017-06-13	Portola Pharmaceuticals, Inc.	Substituted pyrimidinyl kinase inhibitors
PL3049378T3 (pl) *	2013-09-25	2019-06-28	SpecGx LLC	Wytwarzanie radiojodowanego 3-fluoropropylo-nor-beta-CIT
GB201321748D0 (en)	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic agents
WO2023192360A1 (en) *	2022-03-31	2023-10-05	Incelldx, Inc.	Methods of treating a subject for post-treatment lyme disease (ptld) and compositions for use in the same
WO2023192361A1 (en) *	2022-03-31	2023-10-05	Incelldx, Inc.	Methods of treating a subject for fibromyalgia and compositions for use in the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000038680A1 (en) *	1998-12-23	2000-07-06	Pfizer Limited	Azabicycloalkanes as ccr5 modulators
WO2001090106A2 (en) *	2000-05-26	2001-11-29	Pfizer Limited	Tryasolyl tropane derivatives as ccr5 modulators
WO2003084954A1 (en) *	2002-04-08	2003-10-16	Pfizer Limited	Tropane derivatives as ccr5 modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
KR100210417B1 (ko)	1994-04-19	1999-07-15	페더 벨링	신경전달물질 재흡수 억제제인 트로판-2-알독심 유도체
GB9518953D0 (en) *	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
ATE203023T1 (de)	1996-02-22	2001-07-15	Neurosearch As	Tropanderivate, deren herstellung und verwendung
WO2000035298A1 (en)	1996-11-27	2000-06-22	Wm. Wrigley Jr. Company	Chewing gum containing medicament active agents
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
US6855724B2 (en) *	2002-04-08	2005-02-15	Agouron Pharmaceuticals, Inc.	Tropane derivatives useful in therapy

2004
- 2004-09-28 SI SI200430564T patent/SI1682545T1/sl unknown
- 2004-09-28 EP EP04769496A patent/EP1682545B1/en active Active
- 2004-09-28 ES ES04769496T patent/ES2295924T3/es active Active
- 2004-09-28 EA EA200600480A patent/EA009941B1/ru not_active IP Right Cessation
- 2004-09-28 KR KR1020067006293A patent/KR100777885B1/ko not_active IP Right Cessation
- 2004-09-28 MX MXPA06003749A patent/MXPA06003749A/es active IP Right Grant
- 2004-09-28 BR BRPI0414862-2A patent/BRPI0414862A/pt not_active IP Right Cessation
- 2004-09-28 OA OA1200600114A patent/OA13266A/en unknown
- 2004-09-28 AU AU2004278158A patent/AU2004278158B2/en not_active Ceased
- 2004-09-28 DK DK04769496T patent/DK1682545T3/da active
- 2004-09-28 AT AT04769496T patent/ATE380813T1/de active
- 2004-09-28 RS YUP-2006/0198A patent/RS20060198A/sr unknown
- 2004-09-28 DE DE602004010708T patent/DE602004010708T2/de active Active
- 2004-09-28 WO PCT/IB2004/003153 patent/WO2005033107A1/en active IP Right Grant
- 2004-09-28 PL PL04769496T patent/PL1682545T3/pl unknown
- 2004-09-28 JP JP2006530737A patent/JP4874107B2/ja not_active Expired - Fee Related
- 2004-09-28 CA CA2540834A patent/CA2540834C/en not_active Expired - Fee Related
- 2004-09-28 US US10/953,136 patent/US7309790B2/en not_active Expired - Fee Related
- 2004-09-28 PT PT04769496T patent/PT1682545E/pt unknown
- 2004-09-28 AP AP2006003580A patent/AP2174A/xx active
- 2004-09-28 NZ NZ545837A patent/NZ545837A/en not_active IP Right Cessation
- 2004-09-28 GE GEAP20049330A patent/GEP20084417B/en unknown
- 2004-09-29 HN HN2004000383A patent/HN2004000383A/es unknown
- 2004-09-29 TW TW093129475A patent/TWI280244B/zh not_active IP Right Cessation
- 2004-10-01 PA PA20048614301A patent/PA8614301A1/es unknown
- 2004-10-01 UY UY28546A patent/UY28546A1/es unknown
- 2004-10-01 MY MYPI20044043A patent/MY137609A/en unknown
- 2004-10-01 AR ARP040103581A patent/AR045856A1/es not_active Application Discontinuation
- 2004-10-01 PE PE2004000965A patent/PE20050961A1/es not_active Application Discontinuation
2006
- 2006-03-09 IL IL174208A patent/IL174208A0/en unknown
- 2006-04-03 EC EC2006006475A patent/ECSP066475A/es unknown
- 2006-04-03 MA MA28906A patent/MA28080A1/fr unknown
- 2006-05-03 NO NO20061978A patent/NO20061978L/no not_active Application Discontinuation
2007
- 2007-08-27 US US11/845,500 patent/US7790740B2/en not_active Expired - Fee Related
2008
- 2008-01-30 HR HR20080052T patent/HRP20080052T3/xx unknown
- 2008-02-14 CY CY20081100178T patent/CY1107281T1/el unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000038680A1 (en) *	1998-12-23	2000-07-06	Pfizer Limited	Azabicycloalkanes as ccr5 modulators
WO2001090106A2 (en) *	2000-05-26	2001-11-29	Pfizer Limited	Tryasolyl tropane derivatives as ccr5 modulators
WO2003084954A1 (en) *	2002-04-08	2003-10-16	Pfizer Limited	Tropane derivatives as ccr5 modulators

Also Published As

Publication number	Publication date
KR100777885B1 (ko)	2007-11-28
EP1682545A1 (en)	2006-07-26
MXPA06003749A (es)	2006-06-14
SI1682545T1 (sl)	2008-04-30
TW200519112A (en)	2005-06-16
HRP20080052T3 (en)	2008-02-29
TWI280244B (en)	2007-05-01
US20050131011A1 (en)	2005-06-16
US7309790B2 (en)	2007-12-18
US20080045563A1 (en)	2008-02-21
DE602004010708T2 (de)	2008-12-04
ES2295924T3 (es)	2008-04-16
DE602004010708D1 (de)	2008-01-24
PT1682545E (pt)	2008-02-11
KR20060070571A (ko)	2006-06-23
MA28080A1 (fr)	2006-08-01
CY1107281T1 (el)	2012-11-21
MY137609A (en)	2009-02-27
IL174208A0 (en)	2006-08-01
BRPI0414862A (pt)	2006-11-28
DK1682545T3 (da)	2008-03-17
WO2005033107A1 (en)	2005-04-14
US7790740B2 (en)	2010-09-07
JP4874107B2 (ja)	2012-02-15
AU2004278158A1 (en)	2005-04-14
EA200600480A1 (ru)	2006-08-25
ATE380813T1 (de)	2007-12-15
AU2004278158B2 (en)	2009-08-13
OA13266A (en)	2007-01-31
AR045856A1 (es)	2005-11-16
EA009941B1 (ru)	2008-04-28
AP2006003580A0 (en)	2006-04-30
PL1682545T3 (pl)	2008-04-30
NO20061978L (no)	2006-07-03
CA2540834C (en)	2010-06-22
PE20050961A1 (es)	2005-11-29
GEP20084417B (en)	2008-07-10
HN2004000383A (es)	2008-10-14
RS20060198A (xx)	2008-09-29
EP1682545B1 (en)	2007-12-12
UY28546A1 (es)	2005-05-31
CA2540834A1 (en)	2005-04-14
ECSP066475A (es)	2006-10-10
JP2007507483A (ja)	2007-03-29
PA8614301A1 (es)	2005-05-10
NZ545837A (en)	2009-12-24

Publication	Publication Date	Title
AP2174A (en)	2010-11-20	Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflamation.
ZA200702772B (en)	2008-08-27	Quinuclidine derivatives and their use as muscarinic M3 receptor antagonists
IL160974A0 (en)	2004-08-31	Piperazine derivatives with ccr1 receptor antagonist activity
NO20020392D0 (no)	2002-01-25	Nociceptinreseptor ORL-1-agonister for anvendelse ved behandling av hoste
IL165871A0 (en)	2006-01-15	Substituted quinoline CCR5 receptor antagonists
IL178334A0 (en)	2007-02-11	Selected cgrp antagonists, methods for the production thereof and their use as medicaments
DE60021370D1 (de)	2005-08-25	Piperazinderivate verwendbar als ccr5 antagonisten
IL179605A0 (en)	2007-05-15	Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with tetrahydropyridine as crf antagonists
IL174952A0 (en)	2006-08-20	Sulfoximine-substituted pyrimidines for use as cdk and/or vegf inhibitors, the production thereof and their use as drugs
IL160896A0 (en)	2004-08-31	Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
AP1789A (en)	2007-10-05	Tropane derivatives useful in therapy.
IL178622A0 (en)	2007-02-11	Piperazinylpiperidine derivatives as chemokine receptor antagonists
PL369758A1 (en)	2005-05-02	Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
IL183485A0 (en)	2007-10-31	Therapeutic pyrazolo[3,4-b] pyridines and indazoles
AU2003267088A8 (en)	2004-04-30	Chemokine receptor antagonists as therapeutic agents
HK1126200A1 (en)	2009-08-28	Isoquinoline et benzo[h]isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of histamine h3 receptor
AP2005003196A0 (en)	2005-03-31	Bicyclic piperidine derivatives as antagonists of the CCR1 chemokine receptor.
PL372701A1 (en)	2005-07-25	Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane as nmda, 5ht3, and neuronal nicotinic receptor antagonists
SI1644012T1 (sl)	2010-10-29	Kvarterni helidoninski in alkaloidni derivati, postopek za njihovo pripravo in njihova uporaba pri pripravi zdravil
WO2003080118A3 (en)	2004-01-15	Combination of an aldosterone receptor antagonist and a fibric acid derivative
SI1305047T1 (sl)	2006-10-31	Nepeptidni CCR1 receptorski antagonisti v kombinaciji s ciklosporinom A za zdravljenje zavrnitve srcnega transplantata